[Chemotherapy of pancreatic carcinoma].
Patients with advanced pancreatic carcinoma benefit from chemotherapy with gemcitabine or 5-FU based regimens. Promising new combinations schedules with e.g. oxaliplatin, docetaxel, or erlotinib are under development. A survival benefit of adjuvant chemotherapy--after complete surgical resection of the primary tumor--has been demonstrated in some studies.
Lutz
M P
MP
Medizinische Klinik, Gastroenterologie, Caritasklinik St. Theresia, Saarbrücken. m.lutz@caritasklinik.de
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives; D000077143:Docetaxel; D000069347:Erlotinib Hydrochloride; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011799:Quinazolines / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D000093542:Gemcitabine
D009944:Organoplatinum Compounds; D011799:Quinazolines; D043823:Taxoids; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000077143:Docetaxel; D000069347:Erlotinib Hydrochloride; D002955:Leucovorin; D005472:Fluorouracil; D000093542:Gemcitabine